PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24498857-7	2014	ASBT inhibition by RSV was reversed by proteasome inhibitors (MG-132 and lactacystin) and the ubiquitin inhibitor LDN57444, suggesting involvement of the ubiquitin-proteasome pathway.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	62-68	solute carrier family 10 member 2	Homo sapiens	0-4	
15304498-5	2004	Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased ASBT levels and increased intracellular accumulation of ASBT.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	15-21	solute carrier family 10 member 2	Homo sapiens	79-83	
21646357-5	2011	Cell surface expression of G50C and G50A was rescued upon MG132 treatment as well as cyclosporine A, but not by FK506 or bile acids, suggesting that Gly(50) is involved in hASBT folding.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	58-63	solute carrier family 10 member 2	Homo sapiens	172-177	
15304498-5	2004	Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased ASBT levels and increased intracellular accumulation of ASBT.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	15-21	solute carrier family 10 member 2	Homo sapiens	135-139	
31194565-6	2019	Interestingly, PP2-mediated suppression of hASBT protein expression was rescued by the proteasome inhibitor MG132, suggesting that dephosphorylation impacts protein stability with the subsequent proteasome-dependent degradation of hASBT.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	108-113	solute carrier family 10 member 2	Homo sapiens	43-48	
31194565-6	2019	Interestingly, PP2-mediated suppression of hASBT protein expression was rescued by the proteasome inhibitor MG132, suggesting that dephosphorylation impacts protein stability with the subsequent proteasome-dependent degradation of hASBT.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	108-113	solute carrier family 10 member 2	Homo sapiens	231-236